Izzat A M Al-Rayahi1,2, Lee R Machado3, Cordula M Stover1. 1. Department of Respiratory Sciences, University of Leicester, Leicester LE1 9HN, UK. 2. Department of Medical Laboratory Technology, College of Health and Medical Technology, Middle Technical University, Baghdad 10047, Iraq. 3. Centre for Physical Activity and Life Sciences, University of Northampton, Northampton NN1 5PH, UK.
Abstract
Background and Objectives: Tumours are often low immunogenic. The role of complement, an innate immune defence system, in tumour control has begun to be elucidated, but findings are conflicting. A role for properdin, an amplifier of complement activation, in tumour control has recently been implicated. Materials and Methods: Properdin-deficient and congenic wildtype mice were injected subcutaneously with B16F10 melanoma cells. Tumour mass and chemokine profile were assessed. The frequencies of CD45+CD11b+ Gr-1+ cells were determined from tumours and spleens, and CD206+ F4/80+ cells were evaluated in spleens. Sera were analysed for C5a, sC5b-9, and CCL2. Results: Whilst there was no difference in tumour growth at study endpoint, properdin-deficient mice had significantly fewer myeloid-derived suppressor cells (MDSCs) in their tumours and spleens. Splenic M2 type macrophages and serum levels of C5a, sC5b-9, and CCL2 were decreased in properdin-deficient compared to wildtype mice. Conclusions: The presence of intact complement amplification sustains an environment that lessens potential anti-tumour responses.
Background and Objectives:Tumours are often low immunogenic. The role of complement, an innate immune defence system, in tumour control has begun to be elucidated, but findings are conflicting. A role for properdin, an amplifier of complement activation, in tumour control has recently been implicated. Materials and Methods:Properdin-deficient and congenic wildtype mice were injected subcutaneously with B16F10melanoma cells. Tumour mass and chemokine profile were assessed. The frequencies of CD45+CD11b+ Gr-1+ cells were determined from tumours and spleens, and CD206+ F4/80+ cells were evaluated in spleens. Sera were analysed for C5a, sC5b-9, and CCL2. Results: Whilst there was no difference in tumour growth at study endpoint, properdin-deficient mice had significantly fewer myeloid-derived suppressor cells (MDSCs) in their tumours and spleens. Splenic M2 type macrophages and serum levels of C5a, sC5b-9, and CCL2 were decreased in properdin-deficient compared to wildtype mice. Conclusions: The presence of intact complement amplification sustains an environment that lessens potential anti-tumour responses.
Authors: S Izumi; K Hirai; M Miyamasu; Y Takahashi; Y Misaki; T Takaishi; Y Morita; K Matsushima; N Ida; H Nakamura; T Kasahara; K Ito Journal: Eur J Immunol Date: 1997-04 Impact factor: 5.532
Authors: Virna Cortez-Retamozo; Martin Etzrodt; Andita Newton; Philipp J Rauch; Aleksey Chudnovskiy; Cedric Berger; Russell J H Ryan; Yoshiko Iwamoto; Brett Marinelli; Rostic Gorbatov; Reza Forghani; Tatiana I Novobrantseva; Victor Koteliansky; Jose-Luiz Figueiredo; John W Chen; Daniel G Anderson; Matthias Nahrendorf; Filip K Swirski; Ralph Weissleder; Mikael J Pittet Journal: Proc Natl Acad Sci U S A Date: 2012-01-30 Impact factor: 11.205
Authors: Leticia Corrales; Daniel Ajona; Stavros Rafail; Juan J Lasarte; Jose I Riezu-Boj; John D Lambris; Ana Rouzaut; Maria J Pajares; Luis M Montuenga; Ruben Pio Journal: J Immunol Date: 2012-10-01 Impact factor: 5.422
Authors: Melissa G Lechner; Saman S Karimi; Keegan Barry-Holson; Trevor E Angell; Katherine A Murphy; Connor H Church; John R Ohlfest; Peisheng Hu; Alan L Epstein Journal: J Immunother Date: 2013 Nov-Dec Impact factor: 4.456
Authors: Martin Kolev; Madhumita Das; Monica Gerber; Scott Baver; Pascal Deschatelets; Maciej M Markiewski Journal: Front Immunol Date: 2022-07-01 Impact factor: 8.786